develop
replicationdefect
report
viru
pseudotyp
envelop
glycoprotein
equin
infecti
anemia
viru
eiav
vitro
host
rang
neutral
phenotyp
eiav
envpseudotyp
viru
similar
replicationcompet
viru
eiav
env
pseudoviru
improv
antigen
character
viral
variant
evalu
lentiviru
vaccin
abil
lentivirus
continu
evolv
escap
immun
control
central
impedi
develop
effect
vaccin
human
immunodefici
viru
type
lentivirus
despit
enorm
effort
vaccin
elicit
antibodi
neutral
divers
isol
result
consist
protect
challeng
heterolog
pathogen
virus
develop
equin
infecti
anemia
viru
eiav
macrophagetrop
lentiviru
caus
lifelong
persist
infect
hors
hors
infect
eiav
gener
experi
clinic
variabl
diseas
cours
demarc
acut
chronic
inappar
stage
infect
lentivir
infect
adapt
immun
respons
critic
control
acut
eiav
infect
maintain
inappar
stage
importantli
eiavinfect
hors
abl
mount
broadli
reactiv
neutralizingantibodi
respons
reduc
level
replic
viru
longterm
inappar
infect
identif
viral
epitop
target
broadli
reactiv
neutral
antibodi
could
facilit
design
effect
vaccin
eiav
lentivirus
includ
pseudotyp
virus
success
use
character
neutral
antibodi
identifi
broadli
neutral
epitop
mani
virus
includ
hiv
hepat
c
viru
sever
acut
respiratori
syndrom
viru
venezuelan
equin
enceph
viru
studi
develop
eiav
envpseudotyp
report
viru
use
eiavbas
gene
transfer
vector
develop
john
olsen
eiav
env
pseudoviru
readili
transduc
equin
cell
amen
highthroughput
assay
analysi
eiav
broadli
neutral
antibodi
eiav
env
pseudoviru
may
use
tool
identif
neutral
epitop
assess
vaccin
candid
character
eiavreceptor
interact
overal
goal
studi
gener
replicationdefect
report
viru
pseudotyp
eiav
env
would
facilit
immunolog
character
eiav
envelop
glycoprotein
overcom
instabl
eiav
envelop
express
bacteri
cell
surfac
su
transmembran
tm
envelop
sequenc
genbank
access
number
codon
optim
genscript
piscataway
nj
clone
lowcopynumb
vector
grown
max
effici
compet
cell
invitrogen
carlsbad
ca
plasmid
design
plgcosutm
combin
effect
codon
optim
amplif
lowcopynumb
plasmid
result
threefold
increas
stabil
eiav
env
protein
express
confirm
western
blot
use
eiav
convalescentphas
sera
shown
eiav
env
pseudoviru
stock
gener
cotransfect
human
embryon
kidney
cell
atcc
crl
three
plasmid
encod
viral
core
luciferas
report
plasmid
eiav
codonoptim
envelop
plasmid
plgcosutm
describ
control
vesicular
stomat
viru
glycoprotein
vsvg
pseudotyp
viru
gener
use
envelop
plasmid
pcivsvg
largescal
plasmid
purif
perform
endofre
plasmid
maxikit
qiagen
valencia
ca
human
embryon
kidney
produc
cell
transient
transfect
g
envelop
plasmid
g
g
use
profect
mammalian
transfect
system
promega
madison
wi
next
day
mm
sodium
butyr
ad
fresh
media
supernat
collect
h
posttransfect
clarifi
centrifug
aliquot
store
pseudotyp
viru
stock
assess
supernat
revers
transcriptas
activ
transduct
equin
dermal
ed
cell
atcc
ccl
level
pseudoviru
revers
transcriptas
activ
compar
viru
stock
produc
cell
infect
replicationcompet
viru
cpml
supernat
titrat
pseudoviru
ed
cell
seed
cultur
plate
ed
cellswel
dulbecco
modifi
eagl
medium
supplement
antibiot
heatinactiv
fetal
calf
serum
next
day
cell
inocul
serial
dilut
pseudotyp
viru
stock
presenc
gml
polybren
cultur
media
chang
follow
day
cell
assay
brightglo
luciferas
assay
system
promega
madison
wi
h
posttransduct
luminesc
detect
microbeta
trilux
luminomet
perkinelm
boston
titer
report
rel
light
unit
rlu
per
millilit
due
wide
host
cell
rang
vsvg
envelop
wide
use
pseudoviru
product
becom
standard
evalu
pseudotyp
virus
therefor
initi
compar
eiav
env
pseudoviru
titer
vsvg
pseudoviru
pseudoviru
stock
readili
transduc
ed
cell
titer
exceed
rluml
vsvg
eiav
env
pseudovirus
observ
linear
relationship
luciferas
activ
amount
pseudoviru
use
inocul
fig
vitro
host
rang
eiav
env
pseudoviru
investig
transduct
addit
cell
type
known
permiss
eiav
replic
includ
fetal
equin
kidney
ek
cell
canin
fibroblast
cell
atcc
crl
equin
monocytederiv
macrophag
mdm
cell
type
suscept
transduct
eiav
env
pseudoviru
fig
titer
ek
cell
greater
rluml
similar
obtain
ed
cell
transduct
mdm
less
effici
variabl
cell
type
fig
similar
report
replicationcompet
viru
result
indic
eiav
env
pseudoviru
use
fill
squar
eiav
envpseudotyp
viru
eiav
env
open
squar
determin
focu
reduct
assay
luciferas
assay
respect
titer
repres
invers
serum
dilut
requir
neutral
least
viru
infect
c
develop
neutral
antibodi
chimer
env
pseudovirus
eiav
env
fill
circl
eiav
env
open
squar
neutral
antibodi
titer
repres
invers
serum
dilut
requir
neutral
least
luciferas
express
transduc
cell
immunolog
character
eiav
env
pseudoviru
perform
use
wellcharacter
set
longitudin
serum
sampl
obtain
experiment
infect
hors
serum
sampl
collect
sequenti
day
postinocul
heat
inactiv
destroy
complement
serial
dilut
twofold
initi
dilut
incub
approxim
rlu
pseudoviru
hour
inocul
triplic
onto
ed
cell
seed
plate
describ
cell
assay
h
posttransduct
luciferas
activ
percent
neutral
calcul
reduct
number
rlu
compar
number
cell
inocul
viru
result
indic
dosedepend
decreas
neutral
increas
dilut
sera
fig
addit
observ
similar
pattern
develop
neutral
antibodi
eiav
env
pseudoviru
replicationcompet
eiav
fig
eiav
env
pseudoviru
sensit
neutral
report
virus
previous
develop
chimer
infecti
molecular
clone
character
antigen
phenotyp
su
variant
aros
cours
eiav
infect
vivo
determin
whether
eiav
env
pseudoviru
provid
rapid
assay
system
type
analys
region
codonoptim
eiav
envelop
replac
antigen
variant
sequenc
genbank
access
number
genotyp
domin
vivo
env
variant
earli
infect
poni
neutral
antibodi
eiav
aros
appear
neutral
antibodi
heterolog
eiav
viru
consist
previou
result
use
replicationcompet
viru
neutral
antibodi
eiav
env
pseudoviru
detect
earlier
infect
present
higher
titer
neutral
antibodi
eiav
env
pseudoviru
fig
summari
develop
eiav
envpseudotyp
report
viru
system
demonstr
infect
neutral
phenotyp
pseudoviru
recapitul
result
replicationcompet
viru
pseudotyp
viru
system
facilit
studi
eiav
persist
pathogenesi
aid
design
evalu
lentiviru
vaccin
